NAPLEX (North American Pharmacist Licensure Examination) Practice Exam

Disable ads (and more) with a membership for a one time $4.99 payment

Ace your North American Pharmacist Licensure Examination (NAPLEX) with our comprehensive practice test. Features include interactive flashcards, multiple-choice questions, with detailed hints and explanations. Fast-track your pharmacy career today!

Practice this question and more.

Bictegravir, as part of Biktarvy, is noted to increase what in patients?

Blood glucose
SCr (Serum Creatinine)
HDL cholesterol
Hepatic enzymes

The correct answer is: SCr (Serum Creatinine)

Bictegravir, as part of Biktarvy, is noted to increase SCr (Serum Creatinine) in patients. It is important to note that this increase may be temporary and does not necessarily indicate kidney damage. A temporary increase in SCr is expected in patients taking Biktarvy due to the way bictegravir is metabolized in the body. Therefore, options A, C, and D are incorrect because Biktarvy does not directly affect blood glucose, HDL cholesterol, or hepatic enzymes in patients. While these levels may be influenced by other factors, they are not directly impacted by bictegravir in Biktarvy. It is important for patients taking Biktarvy to regularly monitor their kidney function with their healthcare provider to ensure any changes are properly monitored and managed.